alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 75, Number 46 (Wednesday, March 10, 2010)]
[Notices]
[Page 11228]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4938]


-----------------------------------------------------------------------

DEPARTMENT OF THE TREASURY

Fiscal Service


Surety Companies Acceptable on Federal Bonds: Pennsylvania 
Manufacturers Indemnity Company

AGENCY: Financial Management Service, Fiscal Service, Department of the 
Treasury.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is Supplement No. 7 to the Treasury Department Circular 
570, 2009 Revision, published July 1, 2009, at 74 FR 31536.

FOR FURTHER INFORMATION CONTACT: Surety Bond Branch at (202) 874-6850.

SUPPLEMENTARY INFORMATION: A Certificate of Authority as an acceptable 
surety on Federal bonds is hereby issued under 31 U.S.C. 9305 to the 
following company:
    Pennsylvania Manufacturers Indemnity Company (NAIC <greek-i>41424). 
Business.
    Address: P.O. Box 3031, Blue Bell, PA 19422-0754.
    Phone: (610) 397-5000. Underwriting Limitation b/: $7,021,000.
    Surety Licenses c/: AL, AK, AZ, AR, CO, CT, DE, DC, ID, IN, KS, KY, 
LA, ME, MD, MT, MS, MO, MT, NE, NV, NJ, NM, NY, NC, OH, PA, RI, SC, SD, 
TN, UT, VT, VA, WA. Incorporated In: Pennsylvania.
    Federal bond-approving officers should annotate their reference 
copies of the Treasury Circular 570 (``Circular''), 2009 Revision, to 
reflect this addition.
    Certificates of Authority expire on June 30th each year, unless 
revoked prior to that date. The Certificates are subject to subsequent 
annual renewal as long as the companies remain qualified (see 31 CFR 
part 223). A list of qualified companies is published annually as of 
July 1st in the Circular, which outlines details as to the underwriting 
limitations, areas in which companies are licensed to transact surety 
business, and other information.
    The Circular may be viewed and downloaded through the Internet at 
http://www.fms.treas.gov/c570.
    Questions concerning this Notice may be directed to the U.S. 
Department of the Treasury, Financial Management Service, Financial 
Accounting and Services Division, Surety Bond Branch, 3700 East-West 
Highway, Room 6F01, Hyattsville, MD 20782.

    Dated: February 25, 2010.
Vivian L. Cooper,
Director, Financial Accounting and Services Division.
[FR Doc. 2010-4938 Filed 3-9-10; 8:45 am]
BILLING CODE M
Exhibit








EXHIBIT 10.1




AMENDMENT NUMBER ONE
TO THE
REGIONS FINANCIAL CORPORATION
2015 LONG-TERM INCENTIVE PLAN


Regions Financial Corporation hereby amends the Regions Financial Corporation 2015 Long-Term Incentive Plan, effective as of January 1, 2017, as follows:


1.Amend the second sentence in Paragraph 16(f) by replacing such sentence with the following: 


“If the event giving rise to the withholding obligation involves the issue or transfer of shares of Stock, then, unless the applicable Award Agreement provides otherwise, the Committee may permit a Grantee to satisfy the withholding obligation by electing to have the Company withhold shares of Stock or by tendering previously owned shares of Stock, in each case having a Fair Market Value not to exceed the maximum statutory tax rate in the applicable jurisdiction (or by any other mechanism as may be required or appropriate to conform with local tax and other rules).” 


2.Except as otherwise amended herein, the Plan shall continue in full force and effect.




*  *  *  *  *
<PAGE>  1




-----------------------------------------------------------------------------
           UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                       Washington, D.C. 20549
                                10-Q
(Mark One)
        /x/  Quarterly Report Pursuant to Section 13 or Section 15(d)
             of the Securities Exchange Act of 1934

             For the quarterly period ended June 29, 1996
             
OR

        / /  Transition report pursuant to Section 13 or 15(d) of the
             Securities Exchange Act of 1934

             For the transition period from __________ to __________.
  
Commission File No. 0-18033

                         EXABYTE CORPORATION
         (Exact name of registrant as specified in its charter)


       Delaware                        84-0988566
(State of Incorporation)     (I.R.S. Employer Identification No.)

                          1685 38th Street
                      Boulder, Colorado  80301
     (Address of principal executive offices, including zip code)



                          (303) 442-4333
         (Registrant's Telephone Number, including area code)


     Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past ninety days.

      Yes          /X/                      No          /  /


As of July 30, 1996, there were 22,126,112 shares outstanding of the
Registrant's Common Stock (par value $0.001 per share).

-----------------------------------------------------------------------------






<PAGE> 2

PART II.




Item 6.  Exhibits and Reports on Form 8-K

(a)     Exhibit Index

          Exhibit
          Number               Description
          -------              -----------
          27.0                 Financial Data Schedule



(b)     Reports on Form 8-K:  There were no reports on Form 8-K for the
          three month period ended June 29, 1996








































<PAGE> 3





SIGNATURES
----------


Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.



                                  EXABYTE CORPORATION
                                  Registrant



Date                                 By   /s/Stephen F. Smith
      -----------------------             ------------------------
                                         Vice President, Chief Financial
                                         Officer, General Counsel and Secretary
                                         (Principal Financial and Accounting
                                         Officer)
IN THE COURT OF APPEALS OF TENNESSEE

AT KNOXVILLE

IN RE: ESTATE OF MINA RHEA MARTIN

Appeal from the Probate Court for Monroe County

No. 2010-064 Hon. J. Reed Dixon, Judge

No. E2012-00965-COA-R3-CV-FILED-SEPTEMBER 18, 2012

Tenn. R. App. P.3 Appeal as of Right; Appeal Dismissed

HERSCHEL PICKENS FRANKS, P.J., CHARLES D. SUSANO,JR.,J., and JOHN W. MCCLARTY,J.

Ginger Wilson Buchanan, Cleveland, Tennessee, for appellant, Teresa Rucker, Personal

Representative of the Estate.

L. Vincent Williams, Office of the Attorney General, Nashville, Tennessee, for appellee,

State of Tennessee, Bureau of TennCare.

MEMORANDUM OPINION

1

In this action, the Estate has appealed to this Court the denial of an exception to

appellee's claim.

A show cause order was entered in this Court on August 29, 2012, directing counsel

Rule 10 of the Rules of the Court of Appeals provides: "This Court, with the concurrence of all

1

judges participating in the case, may affirm, reverse or modify the actions of the trial court by memorandum

opinion when a formal opinion would have no precedential value. When a case is decided by memorandum

opinion it shall be designated 'MEMORANDUM OPINION,' shall not be published, and shall not be cited

or relied on for any reason in any unrelated case"
for the appellant to show cause why this appeal should not be dismissed for lack of

jurisdiction, based upon the untimely filing of the Notice of Appeal. Counsel for the

appellant has failed to respond to the show cause order within the time specified in that order.

An untimely notice of appeal deprives this Court of jurisdiction. See Tenn. R. App.

P. 4(a). Also see Cobb v. Beier, 944 S.W.2d 343, 344 n.2 (Tenn. 1997).

It is therefore Ordered and Adjudged that this appeal be and hereby is dismissed. The

costs of the appeal are assessed to the Estate of Mina Rhea Martin.

PER CURIAM

-2-
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5870 Thyroid autoantibody immunological test system. ( a ) *Identification.* A thyroid autoantibody immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the thyroid autoantibodies (antibodies produced against the body's own tissues). Measurement of thyroid autoantibodies may aid in the diagnosis of certain thyroid disorders, such as Hashimoto's disease (chronic lymphocytic thyroiditis), nontoxic goiter (enlargement of thyroid gland), Grave's disease (enlargement of the thyroid gland with protrusion of the eyeballs), and cancer of the thyroid.
( b ) *Classification.* Class II (performance standards).
§ 884.4120 Gynecologic electrocautery and accessories. ( a ) *Identification.* A gynecologic electrocautery is a device designed to destroy tissue with high temperatures by tissue contact with an electrically heated probe. It is used to excise cervical lesions, perform biopsies, or treat chronic cervicitis under direct visual observation. This generic type of device may include the following accessories: an electrical generator, a probe, and electrical cables.
( b ) *Classification.* Class II (performance standards).
Nemo

Piedmont

Meade

Pennington

Lawrence

Pennington

Meade

Lawrence

T03NR05E

T03NR06E

T02NR06E T02NR05E

T03NR07E

T04NR05E

T02NR07E

T03NR04E

T04NR06E

T02NR04E

T04NR04E

1

7

6

2

8

4

8

8

3

1

2

9

4

5 4

5

3

5

7

7

2 1

3

9

8

9

6

5

4

9

7

6

8

6

6

7

7

5

8

1

1

11

12

11

11

11

18

31

19

30

31

36

34 32

24

33

25

12

16

26

12

10

36

13

34

14

23

33

32

21

35

17

28

27

12

14

23 24

13

10

22

27 25

31

16

22

15

19

20

29

32 33

10

26

10

21

30

15

35

29

31

18

30 28

19

18

20

17

34

35

17

20

36

29

32

31 32 33

12

36

25

24

13

12

36

13 18 15 14 17

13 18 17 16 14

15 13 18 17 16

25 30 29 28

9

27

0 0.5 1 2 3

Miles

Steamboat Project Area

Wildland Urban Interface

1/2 Mile Structure Buffer

WUI Risk Stands

Steamboat Boundary

Private Land

/
1997 Annual PM2.5 NAAQS Maximum Quarterly Value Data Substitution Test

Average 2011 2012 2013 Number Obs 2011 2012 2013 Completeness 201

Q1 9.6 9.9 11.2 Q1 26 28 28 Q1 8Q2 10.2 11.2 10.9 Q2 29 27 31 Q2 9Q3 12.9 12.1 10.4 Q3 31 22 27 Q3 10Q4 14.4 12.3 12.6 Q4 26 27 31 Q4 8

Annual Average 11.8 11.4 11.3 Annual Count 112 104 117

Average 2011 2012 2013 Number Obs 2011 2012 2013 Completeness 201

Q1 9.6 9.9 11.2 Q1 26.0 28.0 28.0 Q1 8Q2 10.2 11.2 10.9 Q2 29.0 27.0 31.0 Q2 9Q3 12.9 16.2 10.4 Q3 31.0 31.0 27.0 Q3 10

Q4 14.4 12.3 12.6 Q4 26.0 27.0 31.0 Q4 8

Annual Average 11.8 12.4 11.3 Annual Count 112 113 117

Incomplete Quarter Max Value Q3

2011 25.02012 26.32013 18.2

Max Q3 2011‐2013 26.3

Riverside

(Magnolia) DV

Riverside (Magnolia) TDV
Average 2011 2012 2013 Number Obs 2011 2012 2013 Completeness 201

Q1 11.4 11.4 13.4 Q1 30 31 27 Q1 10Q2 10.2 12.1 11.0 Q2 30 30 31 Q2 10Q3 13.9 13.0 10.6 Q3 31 31 29 Q3 10Q4 17.6 13.1 12.9 Q4 27 28 23 Q4 9

Annual Average 13.3 12.4 12.0 Annual Count 118 120 110

Average 2011 2012 2013 Number Obs 2011 2012 2013 Completeness 201

Q1 11.4 11.4 13.4 Q1 30.0 31.0 27.0 Q1 10Q2 10.2 12.1 11.0 Q2 30.0 30.0 31.0 Q2 10Q3 13.9 13.0 10.6 Q3 31.0 31.0 29.0 Q3 10Q4 17.6 13.1 23.2 Q4 27.0 28.0 31.0 Q4 9

Annual Average 13.3 12.4 14.6 Annual Count 118 120 118

Incomplete Quarter Max Value Q4

2011 52.92012 35.22013 49.3

Max Q4 2011‐2013 52.9

Ontario DV Ontario TDV
Average 2011 2012 2013 Number Obs 2011 2012 2013 Completeness 201

Q1 10.5 10.1 12.8 Q1 13 15 14 Q1 8Q2 4.3 5.9 5.7 Q2 15 13 15 Q2 10Q3 5.2 5.1 5.5 Q3 12 10 14 Q3 7Q4 13.8 10.8 14.6 Q4 15 14 16 Q4 10

Annual Average 8.4 8.0 9.7 Annual Count 55 52 59

Average 2011 2012 2013 Number Obs 2011 2012 2013 Completeness 201

Q1 10.5 10.1 12.8 Q1 13.0 15.0 14.0 Q1 8Q2 4.3 5.9 5.7 Q2 15.0 13.0 15.0 Q2 10Q3 5.2 7.0 5.5 Q3 12.0 16.0 14.0 Q3 7

Q4 13.8 10.8 14.6 Q4 15.0 14.0 16.0 Q4 10

Annual Average 8.4 8.4 9.7 Annual Count 55 58 59

Incomplete Quarter Max Value Q3

2011 10.02012 8.02013 9.7

Max Q3 2011‐2013 10.0

Big Bear DV Big Bear TDV
Average 2011 2012 2013 Number Obs 2011 2012 2013 Completeness 201

Q1 9.5 11.1 11.5 Q1 29 27 28 Q1 9Q2 12.1 12.2 11.6 Q2 29 28 27 Q2 9Q3 13.4 12.9 10.6 Q3 21 26 27 Q3 6Q4 14.0 10.9 12.0 Q4 22 26 28 Q4 7

Annual Average 12.2 11.8 11.4 Annual Count 101 107 110

Average 2011 2012 2013 Number Obs 2011 2012 2013 Completeness 201

Q1 9.5 11.1 11.5 Q1 29.0 27.0 28.0 Q1 9Q2 12.1 12.2 11.6 Q2 29.0 28.0 27.0 Q2 9Q3 20.3 12.9 10.6 Q3 31.0 26.0 27.0 Q3 10Q4 27.6 10.9 12.0 Q4 30.0 26.0 28.0 Q4 10

Annual Average 17.4 11.8 11.4 Annual Count 119 107 110

Incomplete Quarter Max Value Q3 Q4

2011 26.6 65.02012 34.8 33.52013 23.7 55.3

Max Q3/Q4 2011‐2013 34.8 65.0

San BernardinoDV San Bernardino TDV
EXHIBIT 11 - CALCULATION OF NET INCOME (LOSS) PER COMMON SHARE

                                 MICROAGE, INC.
                 NET INCOME (LOSS) PER COMMON SHARE CALCULATION
                                 (in thousands)

<TABLE>
<CAPTION>
                                                    Quarter ended              26 weeks ended
                                                ----------------------     ---------------------
                                                   May 2,       May 3,       May 2,       May 3,
                                                   1999         1998         1999         1998
                                                ---------     --------     ---------     --------
<S>                                                <C>          <C>           <C>          <C>
BASIC
  Weighted average common shares                   20,481       19,584        20,412       19,520
                                                ---------     --------     ---------     --------
DILUTED
  Weighted average shares from
   basic calculation                               20,481       19,584        20,412       19,520

  Dilutive effect of stock options
   and warrants                                        --           --            --           --
                                                ---------     --------     ---------     --------
    Weighted average common and common
     equivalent shares outstanding - diluted       20,481       19,584        20,412       19,520
                                                ---------     --------     ---------     --------

NET INCOME  (LOSS)                              $(147,341)    $ (5,957)    $(145,275)    $(12,073)

Net income (loss) per common and
 common equivalent share:
  Basic                                         $   (7.19)    $  (0.30)    $   (7.12)    $  (0.62)
                                                =========     ========     =========     ========
  Diluted                                       $   (7.19)    $  (0.30)    $   (7.12)    $  (0.62)
                                                =========     ========     =========     ========
</TABLE>
From: "Higgins, Cortney" <Cortney_Higgins@omb.eop.gov> To: RobertJ Wayland/RTP/USEPA/US@EPA, Thomas Gillis/DC/USEPA/US@EPA, Karen Thundiyil/DC/USEPA/US@EPA
Date: 12/05/2011 11:03 AM Subject: FW: E.O. 12866 Meeting on EGU MACT Rule

Hi all, Consistent with the EO, attached are the handouts from this meeting.

Regards,
Cortney

-----Original Appointment----- From: Echols, Mabel E. Subject: E.O. 12866 Meeting on EGU MACT Rule When: Friday, December 02, 2011 11:00 AM-11:30 AM (UTC-05:00) Eastern
Time (US & Canada). Where: Eisenhower Room, White House Conference Center

This meeting was requested by Hewitt Strange, Podesta Group.
Editorial Note on Part 882
Editorial Note: Nomenclature changes to part 882 appear at 73 FR 35341, June 23, 2008.

§ 882.5801 Computerized behavioral therapy device for psychiatric disorders. ( a ) *Identification.* A computerized behavioral therapy device for psychiatric disorders is a prescription only device intended to provide a computerized version of condition-specific behavioral therapy as an adjunct to clinician supervised outpatient treatment to patients with psychiatric conditions. The digital therapy is intended to provide patients access to therapy tools used during treatment sessions to improve recognized treatment outcomes.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Clinical data must be provided to fulfill the following: ( i ) Describe a validated model of behavioral therapy for the psychiatric disorder; and
( ii ) Validate the model of behavioral therapy as implemented by the device.
( 2 ) Software must be described in detail in the software requirements specification (SRS) and software design specification (SDS). Software verification, validation, and hazard analysis must be performed. Software documentation must demonstrate that the device effectively implements the behavioral therapy model.
( 3 ) The following labeling must be provided: ( i ) Patient and physician labeling must include instructions for use, including images that demonstrate how to interact with the device.
( ii ) Patient and physician labeling must list compatible devices.
( iii ) Patient and physician labeling must include a warning that the device is not intended for use as a standalone therapy.
( iv ) Patient and physician labeling must include a warning that the device does not represent a substitution for the patient's medication.
( v ) Physician labeling must include a summary of the clinical testing with the device.
[82 FR 61167, Dec. 27, 2017]
§ 1.167(l)-4 Public utility property; election to use asset depreciation range system. ( a ) *Application of section 167(l) to certain property subject to asset depreciation range system.* If the taxpayer elects to compute depreciation under the asset depreciation range system described in § 1.167(a)-11 with respect to certain public utility property placed in service after December 31, 1970, see § 1.167(a)-11(b) (6).
(Sec. 167 of the Internal Revenue Code of 1954 (26 U.S.C. 167) and sec. 7805 of the Internal Revenue Code of 1954 (26 U.S.C. 7805))
[T.D. 7128, 36 FR 11939, June 23, 1971. Redesignated by T.D. 7315, 39 FR 20203, June 7, 1974]
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.2600 Signal isolation system. ( a ) *Identification.* A signal isolation system is a device that electrically isolates the patient from equipment connected to the commercial power supply received from a utility company. This isolation may be accomplished, for example, by transformer coupling, acoustic coupling, or optical coupling.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.
[45 FR 7907, Feb. 5, 1980, as amended at 61 FR 1121, Jan. 16, 1996; 66 FR 38796, July 25, 2001]
Editorial Note on Part 890
Editorial Note: Nomenclature changes to part 890 appear at 73 FR 35341, June 23, 2008.

§ 890.5150 Powered patient transport. ( a ) *Powered patient stairway chair lifts* — ( 1 ) *Identification.* A powered patient stairway chair lift is a motorized lift equipped with a seat and permanently mounted in one location that is intended for use in mitigating mobility impairment caused by injury or other disease by moving a person up and down a stairway.
( 2 ) *Classification.* Class II. The stairway chair lift is exempt from premarket notification procedures in subpart E of part 807 of this chapter, subject to § 890.9 and the following conditions for exemption: ( i ) Appropriate analysis and nonclinical testing (such as that outlined in the currently FDA-recognized edition of American Society of Mechanical Engineers (ASME) A18.1 “Safety Standard for Platform Lifts and Stairway Chair Lifts”) must demonstrate that the safety controls are adequate to prevent a free fall of the chair in the event of a device failure;
( ii ) Appropriate analysis and nonclinical testing must demonstrate the ability of the device, including armrests, to withstand the rated load with an appropriate factor of safety;
( iii ) Appropriate restraints must be provided to prevent the user from falling from the device (such as that outlined in the currently FDA-recognized edition of ASME A18.1 “Safety Standard for Platform Lifts and Stairway Chair Lifts”);
( iv ) Appropriate analysis and nonclinical testing (such as that outlined in the currently FDA-recognized editions of AAMI/ANSI/IEC 60601-1-2, “Medical Electrical Equipment—Part 1-2: General Requirements for Safety—Collateral Standard: Electromagnetic Compatibility—Requirements and Tests,” and ASME A18.1 “Safety Standard for Platform Lifts and Stairway Chair Lifts”) must validate electromagnetic compatibility and electrical safety; and
( v ) Appropriate analysis and nonclinical testing must demonstrate the resistance of the device upholstery to ignition.
( b ) *All other powered patient transport* — ( 1 ) *Identification.* A powered patient transport is a motorized device intended for use in mitigating mobility impairment caused by injury or other disease by moving a person from one location or level to another, such as up and down flights of stairs (e.g., attendant-operated portable stair-climbing chairs). This generic type of device does not include motorized three-wheeled vehicles or wheelchairs.
( 2 ) *Classification.* Class II.
[78 FR 14017, Mar. 4, 2013]
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.3340 Extraocular orbital implant. ( a ) *Identification.* An extraocular orbital implant is a nonabsorbable device intended to be implanted during scleral surgery for buckling or building up the floor of the eye, usually in conjunction with retinal reattachment. Injectable substances are excluded.
( b ) *Classification.* Class II.
Editorial Note on Part 892
Editorial Note: Nomenclature changes to part 892 appear at 73 FR 35341, June 23, 2008.

§ 892.1170 Bone densitometer. ( a ) *Identification.* A bone densitometer is a device intended for medical purposes to measure bone density and mineral content by x-ray or gamma ray transmission measurements through the bone and adjacent tissues. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.
( b ) *Classification.* Class II.